In patients with type 2 diabetes, glycemic variability may be reduced by the use of glucose-dependent glucose-lowering drugs (e.g., metformin, dipeptidyl-peptidase 4 inhibitors (DPP-4is), sodium-glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP-1RAs)) and lifestyle changes (e.g., low-carbohydrate diet and exercise) [31]. Here, GLP1R is linked to type 2 diabetes mellitus.